Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, ...

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...

AbbVie Inc. and other drug makers lost a bid to block a Tennessee law regulating contracts between pharmaceutical companies ...

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

The 340B prescription drug discount program is an incredibly valuable resource. It requires pharmaceutical companies to give sizeable discounts on prescription drugs to eligible safety-net hospitals a ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.